Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer
Phase PHASE1, PHASE2
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HRS-8080; SHR-A1811 — Participants will receive HRS-8080 and SHR-A1811
  • Drug: HRS-8080; SHR-A2009 — Participants will receive HRS-8080 and SHR-A2009
  • Drug: SHR-A2009; SHR-1316 — Participants will receive SHR-A2009 and SHR-1316

Primary Outcomes

  • Dose Limited Toxicity(DLT) (up to 1 cycle (21 days))
  • Maximum Tolerable Dose(MTD) (up to 1 cycle (21 days))
  • Recommended Phase 2 Dose(RP2D) (up to 1 cycle (21 days))
  • Safety endpoints: the incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (rated based on CTCAE V5.0) (up to 12 months)
  • Efficacy endpoint: objective response rate (ORR) (up to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-02-20
Completion: 2026-10-31
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shandong Suncadia Medicine Co., Ltd.
Contact Information
Study Contact:
Na An
+86 18500038119
na.an@hengrui.com
Quchang Ouyang
13973135318
oyqc1969@126.com
Hunan Cancer Hospital
Quchang Ouyang
Hunan Cancer Hospital
Interventions
  • Drug: HRS-8080; SHR-A1811 — Participants will receive HRS-8080 and SHR-A1811
  • Drug: HRS-8080; SHR-A2009 — Participants will receive HRS-8080 and SHR-A2009
  • Drug: SHR-A2009; SHR-1316 — Participants will receive SHR-A2009 and SHR-1316
Study Locations (1 sites)
Hunan Cancer Hospital, Changsha, Hunan 410031 China
Eligibility Criteria
Inclusion Criteria: 1. Females aged 18-75 years old (both ends inclusive); 2. ECOG performance status (PS) 0-1 points; 3. Patients with metastatic or locally advanced breast cancer confirmed by histology(ER positive, HER2 positive/negative,or triple negative breast cancer). 4. Tumor tissue samples must be provided for detection of tumor markers; 5. Menopausal state; 6. Disease progression confirmed by imaging during or after the last systemic treatment before enrollment; 7. There must be at least one measurable extracranial lesion that complies with RECIST v1.1; 8. Expected survival \>3 months; 9. Good functional level of the organs ; 10. Female subjects with childbearing potential must agree to use highly effective contraceptive measures during the study treatment period and within 7 months after the end of the study treatment period; female subjects with childbearing potential must agree to use serum serum within 7 days before study enrollment. The HCG test must be negative and the patient must be non-lactating; 11. Voluntarily participate in this clinical trial, be willing and able to comply with clinical visits and research-related procedures, understand the research procedures and have signed informed consent. Exclusion Criteria: 1. Patients with active (without medical control or clinical symptoms) brain metastasis; 2. Have the following lung diseases or history; 3. History of clinically severe cardiovascular disease; 4. Those who have received immunosuppressants or systemic hormone therapy for immunosuppression within 2 weeks before the first dose (dose \>10 mg/d prednisone or other corticosteroids at equivalent physiological doses), excluding nasal spray or inhaled hormones; 5. The damage caused by the subject receiving other treatments has not recovered (severity level NCI-CTCAE V5.0 classification ≤1, excluding hair loss and other adverse events judged to be tolerable by the researcher); 6. There are serious infections within 4 weeks before the first medication; 7. Untreated active hepatitis; 8. The subject has suffered from other malignant tumors in the past 5 years or currently, excluding cured cervical carcinoma in situ, cutaneous basal cell carcinoma and squamous cell carcinoma; 9. Presence of active autoimmune disease; 10. Have a history of immunodeficiency, including acquired (HIV infection), congenital immunodeficiency diseases, or a history of organ transplantation (including allogeneic bone marrow transplantation); 11. The subject is in the acute infection stage or active tuberculosis and requires drug treatment; 12. Known to be allergic to the components of HRS-8080, SHR-A1811 and its components, SHR-A2009 and its components, and Adebrelimab; have a history of severe allergic reactions to other monoclonal antibodies; 13. Patients who have other serious physical or mental illnesses or laboratory test abnormalities that may increase the risk of participating in the study or interfere with the results of the study, and who the researcher believes are not suitable for participation in this study.
Conditions HER2-positive Breast Cancer
Phase NA
Enrollment 94
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This study is to explore the markers in early prediction of the efficacy of pre-operative pertuzumab plus trastuzumab (PH) combined with chemotherapy for early stage or locally advanced human epidermal growth factor receptor-2 (HER-2) positive primary breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: TCHP — Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6 Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w). All study drugs were administered intravenously. Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery.

Primary Outcomes

  • Percent Change in Standardized Uptake Value (SUV) on Positron Emission Tomography and Change in Gene Expression With Response (From baseline to day 15)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-04-21
Completion: 2030-04-30
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 94 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Jiong Wu, MD
+862164175590
wujiong1122@vip.sina.com
Jiong Wu, MD
+862164175590
wujiong1122@vip.sina.com
Shanghai Cancer Center, Fudan University
Interventions
  • Diagnostic Test: TCHP — Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6 Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w). All study drugs were administered intravenously. Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery.
Study Locations (1 sites)
Shanghai Cancer Center, Fudan University, Shanghai, Shanghai Municipality 200000 China
Eligibility Criteria
Inclusion Criteria: 1. Female or male, presenting for the first time with operable breast cancer, who had not received any previous treatment for an invasive malignancy. 2. Primary tumor greater than (\>) 2 cm in diameter. 3. Age ≥ 18 years and \< 70 years. 4. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\</=) 1. 5. Baseline left ventricular ejection fraction (LVEF) greater than or equal to (\>/=) 55% 6. Availability of tumor tissue specimen after surgery. 7. Participants agree to undergo a core needle biopsy for genomic testing and organoid drug sensitivity assay. 8. Histologically proven diagnosis of breast cancer. 9. Patients have HER2-positive disease. HER2-positive disease was defined as follows: disease which overexpresses HER-2 by immunohistochemistry (IHC) 3+ and/or has HER2 amplification according to fluorescence in situ hybridization (FISH). 10. Had hormonal receptors (ER and PgR) assessed. 11. Signed informed consent. 12. Able to comply with the protocol. Exclusion Criteria: 1. Metastatic disease (Stage IV) or bilateral breast cancer. 2. Any previous systemic therapy (including chemotherapy, immunotherapy, HER2 targeted agents, and antitumor vaccines) for cancer, or radiation therapy for cancer. 3. Prior breast or non-breast malignancy within 5 years prior to study entry. 4. Inadequate bone marrow, renal, or liver function 5. History or evidence of cardiovascular condition 6. Severe, uncontrolled systemic disease 7. Participants with poorly controlled diabetes or with evidence of clinically significant diabetic vascular complications. 8. Pregnancy or breast-feeding women. 9. Participants who received any investigational treatment within 4 weeks of study start. 10. Participants with known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus. 11. Current chronic daily treatment with corticosteroids (dose \>10 mg methylprednisolone or equivalent \[excluding inhaled steroids\]). 12. Known hypersensitivity to any of the study drugs or excipients
Conditions Breast Cancer
Phase Not Applicable
Enrollment 1200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Our objective in this study is to identify an optimal set of quantitative ultrasound parameters that can be used, non-invasively, to characterize breast masses with high accuracy, as determined histopathologically. Breast cancer is the most frequent form of non-epithelial cancer diagnosed in women, with approximately 1.5 million new cases diagnosed annually worldwide. Accurate diagnosis and characterization of disease play an important role in therapy planning for breast cancer treatment. Currently, the gold standard method of tumour diagnosis is pathological examination of core biopsy specimens. However, the invasive core biopsies can cause post-surgical complications. Besides, some lesions require repeat biopsy due to sampling errors during the initial biopsy. Also X-ray mammography and ultrasound B-mode images, which are used by radiologists for breast examination, lack reliable information about micro-structural properties of tissues. There is an urgent need of a non-invasive imaging modality that can provide rapid and quantitative information for breast tumour characterization, in real time and at the patient bed. The main goal, as described above, is to select the best quantitative ultrasound parameters that can facilitate breast cancer characterization, non-invasively.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Select the best quantitative ultrasound parameters that can facilitate breast cancer characterization, non-invasively (Up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2014-09-23
Completion: 2029-09
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunnybrook Health Sciences Centre
Principal Investigators:
  • Gregory J Czarnota, PhD, MD (PRINCIPAL_INVESTIGATOR) - Sunnybrook Health Sciences Centre
Contact Information
Study Contact:
Gregory J Czarnota, PhD, MD
(416)480-6128
gregory.czarnota@sunnybrook.ca
Schontal Halstead
416-480-6100
Gregory J Czarnota, PhD, MD
(416)480-6128
gregory.czarnota@sunnybrook.ca
Sunnybrook Health Sciences Centre
Interventions
N/A
Study Locations (1 sites)
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada
Eligibility Criteria
Inclusion Criteria: 1. Women or men with suspected breast cancer 2. Patients should have the ability to understand and the willingness to sign a written Informed consent document. Exclusion Criteria: 1. Patients who have had chemotherapy, radiotherapy, or major surgery within 4 weeks prior to registering in the study or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to registration 2. Receiving any other investigational agents 3. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
Conditions Breast Cancer, Metastatic Breast Cancer,...
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Nicotinamide Riboside — Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy
  • Dietary Supplement: Placebo — Matching placebo b.i.d as long as the patient is receiving anthracycline therapy

Primary Outcomes

  • Whether the administration of nicotinamide riboside can prevent the reduction in left ventricular systolic function measured by cardiovascular magnetic resonance (CMR), compared to placebo. (Baseline, 3 months, 6 months for patients receiving extended chemotherapy, and extended follow up 12 months after initiation of chemotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-03-16
Completion: 2035-09-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Akershus
Collaborators: ChromaDex, Inc., Norwegian Cancer Society, Norwegian Breast Cancer Association, Helse Sor-Ost
Principal Investigators:
  • Torbjørn Omland, MD, PhD (PRINCIPAL_INVESTIGATOR) - University Hospital, Akershus
Contact Information
Study Contact:
Torbjørn Omland, MD, PhD
+47 40107050
torbjorn.omland@medisin.uio.no
Victoria Vinje, MD
+47 92033665
victoria.vinje@ahus.no
Torbjørn Omland, MD, PhD
+47 40107050
torbjorn.omland@medisin.uio.no
Akershus University Hospital
Interventions
  • Dietary Supplement: Nicotinamide Riboside — Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy
  • Dietary Supplement: Placebo — Matching placebo b.i.d as long as the patient is receiving anthracycline therapy
Study Locations (1 sites)
Akershus University Hospital, Lørenskog, Akershus 1478 Norway
Eligibility Criteria
Inclusion Criteria: * Women with metastatic breast cancer (stage IV breast cancer) scheduled for anthracycline-containing chemotherapy * Eastern Cooperative Oncology Group performance status 0-2 Exclusion Criteria * Age \<18 years * Acute myocardial infarction within the last three months * Participation in another pharmaceutical clinical trial of an investigational medicinal product (IMP) less than 4 weeks prior to inclusion or use of other investigational drugs within 5 half-lives of enrollment, whichever is longer * Conditions that would affect the participants to comply with the study protocol as psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected poor drug compliance, language barriers * Life expectancy \< 6 months * Known allergy to any of the components in the Nicotinamide Riboside (Niagen®) tablet * Contraindications or inability to undergo CMR examination
Conditions Metastatic Breast Cancer, Advanced Breas...
Phase PHASE2
Enrollment 139
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC). Participants have to be hormone-receptor positive (HR+) and have to be resistant to endocrine therapy and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. Participants may have received multiple lines of endocrine therapy with or without targeted therapies and must have received only one line of chemotherapy for ABC. Moreover, the immune effects, the predictors of resistance and response to treatment, the effect of the chemotherapy on deoxyribonucleic acid (DNA) replication will be assessed and will help identify the subgroups that will mostly benefit from the treatment. The pharmacokinetics of the product and the anti-drug antibody (ADA) will be also evaluated. A total of 99 participants are planned to be treated in the study. Participants will receive, every three weeks, a dose of U3-1402 equivalent to 5.6 mg/kg of body weight until progression or until unacceptable toxicity. Tumor evaluation will be performed every six weeks by the mean of a computed tomography for the thorax, abdomen and pelvis (TAP CT-scan) or a magnetic resonance imaging (MRI). Brain and/or bone CT scans will be also performed throughout the study for participants with brain and/or bone metastasis. A PET scan combined with contrast enhanced CT scan can replace all the above-mentioned imaging if performed at baseline considering that the same imaging technique should be used throughout the study. The safety of the product will be assessed at each cycle, through complete clinical exams, biological tests, electrocardiograms (ECGs), cardiac echographies (ECHOs) and through the collection of ongoing toxicities or adverse events.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: U3-1402 — U3-1402 is uniquely designed to target HER3-a receptor that contributes to treatment resistance and poor prognosis in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients. This drug is distinct from other interventions due to its composition as an antibody-drug conjugate (ADC): a monoclonal antibody against HER3 conjugated to a topoisomerase I inhibitor, which specifically targets HER3-overexpressing tumor cells. The drug is delivered via a cleavable linker that allows for controlled release of the chemotherapeutic agent within the cancer cells, minimizing systemic side effects.

Primary Outcomes

  • Evaluation of objective response rate (ORR) based on investigator assessment (During treatment period, an average of 8 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-05-11
Completion: 2030-04-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 139 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Collaborators: Daiichi Sankyo
Principal Investigators:
  • Barbara PISTILLI, Dr (STUDY_DIRECTOR) - Gustave Roussy, Cancer Campus, Grand Paris
Contact Information
Study Contact:
Barbara PISTILLI, MD
+33 (0)1 42 11 42 11
barbara.pistilli@gustaveroussy.fr
Souad COSSÉ
+33 (0)1 42 11 42 11
souad.cosse@gustaveroussy.fr
Elise DELUCHE, MD
CHU de Limoges
Interventions
  • Drug: U3-1402 — U3-1402 is uniquely designed to target HER3-a receptor that contributes to treatment resistance and poor prognosis in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients. This drug is distinct from other interventions due to its composition as an antibody-drug conjugate (ADC): a monoclonal antibody against HER3 conjugated to a topoisomerase I inhibitor, which specifically targets HER3-overexpressing tumor cells. The drug is delivered via a cleavable linker that allows for controlled release of the chemotherapeutic agent within the cancer cells, minimizing systemic side effects.
Study Locations (11 sites)
Centre Georges François Leclerc, Dijon, 21079 France
CHU de Limoges, Limoges, 87042 France
Centre Léon Bérard, Lyon, 69373 France
Institut Paoli Calmettes, Marseille, 13273 France
Institut Régional du Cancer de Montpellier, Montpellier, 34298 France
Centre Antoine Lacassagne, Nice, 06189 France
Institut Curie, Paris, 75005 France
Hôpital Tenon, Paris, 75020 France
Institut de Cancérologie de l'Ouest, Saint-Herblain, 44805 France
Institut Claudius Regaud, Toulouse, 31059 France
Eligibility Criteria
Inclusion Criteria: * Adults with histologically-confirmed HER2 negative, unresectable locally advanced or metastatic breast cancer that is hormone receptor positive (HR+) at the time of the first breast cancer diagnosis * Participants with a documented radiologic unresectable or metastatic progression * Participants may have received anthracyclines and taxanes as (neo) adjuvant treatment and must have received one line of chemotherapy for Advanced breast cancer (ABC), but not more than one line. Participants must have a clinically or radiologically documented evidence of tumor progression on or after cyclin dependent kinase 4/6 (CDK 4/ 6) inhibitor combined with endocrine therapy. Previous treatments with PI3K inhibitors, mTOR inhibitors, AKT-inhibitors and poly ADP ribose polymerase (PARP)-inhibitors are allowed * Participants must have a tumor site easily accessible to biopsy (with exception of bone metastasis) * Participants must have at least one radiologically measurable lesion (different from the biopsy site) * Participants must have an ECOG PS equals to 0 or 1 * Participants must have a life expectancy of 12 weeks or more * Participants must have adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to Cycle 1, Day 1 * Female patients of reproductive/childbearing potential must have a negative pregnancy test at screening (serum test within 14 days or urine test within 72 hours of enrollment). A positive urine pregnancy test result must be confirmed by a serum test. Patients must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months after the last dose of study drug. The following contraception methods are considered highly effective: 1. Hormonal or nonhormonal intrauterine device (IUD) 2. Progestogen-only subdermal contraceptive implant 3. Bilateral tubal occlusion 4. Vasectomized partner 5. Complete sexual abstinence defined as refraining from heterosexual intercourse during and upon completion of the study and for at least 7 months for females after the last dose of study drug. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. Penile/external condoms for male partners must be used in addition to the female patient's hormonal contraception for the duration treatment intervention and until 7 months following the last dose of trial intervention. Female patients must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration. * A male participant capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate each trial intervention. The length of time required to continue contraception after last dose for each trial intervention is 4 months. Avoid donating sperm. Note: Preservation of sperm should be considered prior to enrollment/randomization in this trial. Use a penile/external condom when having penile-vaginal intercourse with a nonparticipant of childbearing potential, PLUS partner use of an additional contraceptive method (see below), as a condom may break or leak: 1. Progestogen-only contraceptive implant 2. Hormonal or nonhormonal IUD 3. Bilateral tubal occlusion (includes tubal ligation) 4. Combined (estrogen- and progestogen-containing) hormonal contraception (oral, intravaginal, transdermal, injectable) 5. Progestogen-only hormonal contraception (oral, injectable) 6. Progesterone-only hormonal contraception where inhibition of ovulation is not the primary mode of action 7. Cervical cap, diaphragm, or sponge with spermicide Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the trial interventions are more stringent than the requirements above, the local label requirements are to be followed. Note: If the participant is azoospermic (vasectomized or secondary to medical cause, documented from the site personnel's review of the participant's medical records, medical examination, or medical history interview), no contraception is required. Male participants must not freeze or donate sperm starting at screening and throughout the study period, and for at least 4 months after the final study drug administration * Participant must understand, sign, and date the written ICF prior to any protocol-specific procedures performed. Participant should be able and willing to comply with study visits and procedure as per protocol * Participant must be affiliated to a social security system or beneficiary of the same Exclusion Criteria: * Breast cancer amenable for resection or radiation therapy with curative intent * Any history of interstitial lung disease (ILD), actual ILD, or a suspicion of an ILD * Clinically severe pulmonary compromise (based on investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to: 1. Any underlying pulmonary disorder 2. Any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement 3. OR prior pneumonectomy * The use of chronic systemic corticosteroids at a dose superior to 10 mg daily of prednisone or equivalent or any form of immunosuppressive therapy prior to Cycle 1 Day 1. Participants who require use of bronchodilators, inhaled steroids, or local steroid injections may be included in the study * Evidence of any leptomeningeal disease * Evidence of corneal disease * Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection, psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the investigator's opinion makes it undesirable for the participant to participate in the study or which would jeopardize compliance with the protocol * Evidence of clinically active spinal cord compression or brain metastases defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms * Exposure to prior systemic anticancer therapy (including investigational agents) within 4 weeks or 5 half-lives (whichever is shorter) before enrollment. * Inadequate washout period prior to Cycle 1 Day 1, defined as: 1. Whole brain radiation therapy \<14 days or stereotactic brain radiation therapy \<7 days. 2. Immune checkpoint inhibitor therapy \<21 days 3. Hormonal therapy \<21 days 4. Major surgery (excluding placement of vascular access) \<28 days. 5. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation \<28 days or palliative radiation therapy \<14 days. 6. Chloroquine or hydroxychloroquine ≤ 14 days 7. Live virus vaccination \<28 days. * Prior treatment with an anti-HER3 antibody and/or ADC containing an exatecan derivative that is a topoisomerase I inhibitor * Participants with a grade equals or greater than 2 unresolved toxicities from previous anticancer therapy (other than alopecia) * A history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of U3-1402, or to other monoclonal antibodies * Any evidence of primary malignancy other than locally advanced or metastatic lung cancer within three years prior to Cycle 1 Day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated * Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day : 1. Corrected QT interval higher than 470 ms for females and 450 ms for males according to Fridericia's formula (QTcF) and assessed based on triplicate ECGs, approximately 1 minute apa
Conditions Breast Cancer, Heart Failure
Phase PHASE2
Enrollment 130
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can cause injury to the heart, and this is one of the main reasons it cannot be administered as planned. Heart injury can often be successfully treated using cardiac medications. The objectives of SCHOLAR-2 are to evaluate whether is it safe and effective to continue trastuzumab, pertuzumab or trastuzumab-emtansine (T-DM1) in patients with early stage HER-2 positive breast cancer despite mild, minimally symptomatic or asymptomatic systolic left ventricular dysfunction as compared with a guideline-driven approach of withholding or discontinuing trastuzumab, pertuzumab or trastuzumab-emtansine (T-DM1). In SCHOLAR-2, we will compare two thresholds of withholding or discontinuing trastuzumab/pertuzumab/trastuzumab-emtansine: a threshold that is currently advocated for by existing treatment practice guidelines versus a more aggressive threshold that allows trastuzumab/pertuzumab/trastuzumab-emtansine to continue at lower levels of LVEF than currently supported by guideline documents.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Trastuzumab — Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
  • Drug: Pertuzumab — Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
  • Drug: Trastuzumab emtansine — Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.

Primary Outcomes

  • primary efficacy outcome (one year)
  • co-primary safety outcomes (one year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-07-01
Completion: 2026-06-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Population Health Research Institute
Principal Investigators:
  • Darryl Leong, PhD. MBBSm (PRINCIPAL_INVESTIGATOR) - McMaster University
  • Som Mukherjee, MD MSc FRCPC (PRINCIPAL_INVESTIGATOR) - Hamilton Health Sciences Corporation
Contact Information
Study Contact:
Maha Mushtaha, BSc
9052973479
maha.mushtaha@phri.ca
Sumathy Rangarajan, MSc
9052973479
sumathy.rangarajan@phri.ca
Nathalia Santos
natsantos@haoc.com.br
Hospital de Clínicas de Porto Alegre
Interventions
  • Drug: Trastuzumab — Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
  • Drug: Pertuzumab — Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
  • Drug: Trastuzumab emtansine — Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
Study Locations (8 sites)
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul 90035903 / 90410000 Brazil
Irmandade Da Santa Casa De Misericórdia De Porto Alegre, Porto Alegre, Rio Grande do Sul 90050-170 Brazil
Hospital Alemão Oswaldo Cruz, São Paulo, São Paulo 01327-903 Brazil
Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda, São Paulo, São Paulo 1317000 Brazil
Juravnski Cancer Centre, Hamitlon, Ontario Canada
Ottawa Hospital Research Institute, Ottawa, Ontario Canada
Toronto General Hospital, University Health Network, Toronto, Ontario M5G 2N2 Canada
E.Meshalkin National medical research center of the Ministry of Health of the Russian Federation, Novosibirsk, 630055 Russia
Eligibility Criteria
Inclusion Criteria: 1. Stage I-III HER-2 positive breast cancer 2. Receiving adjuvant or neoadjuvant therapy with trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) 3. Evidence of left ventricular dysfunction, as defined by at least one of: a) LVEF \< 54% or b) LVEF ≥54% and either i) fall in LVEF of ≥15% from prior to trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) exposure, or ii) New York Heart Association (NYHA) class II heart failure symptoms within the past 6 months Exclusion Criteria: 1. Current use of both angiotensin converting enzyme inhibitor (ACEI) /angiotensin receptor blocker (ARB) and beta-blocker 2. Contra-indication to both ACE-I/ARB and beta-blockers 3. NYHA class III or IV heart failure 4. LVEF \<40% 5. Systolic blood pressure \<100mmHg 6. Current or planned pregnancy or breastfeeding
Conditions Brain Metastases, HR+ Metastatic Breast ...
Phase PHASE1, PHASE2
Enrollment 31
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Stereotactic Radiosurgery (SRS) — Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
  • Drug: Abemaciclib — Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
  • Drug: Endocrine therapy — Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.

Primary Outcomes

  • Intracranial Progression Free Survival (PFS) (Up to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-11-30
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 31 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Eli Lilly and Company
Principal Investigators:
  • Kamran A Ahmed, MD (PRINCIPAL_INVESTIGATOR) - Moffitt Cancer Center
  • Heather Han, MD (PRINCIPAL_INVESTIGATOR) - Moffitt Cancer Center
Contact Information
Study Contact:
Kamran A Ahmed, MD
813-745-8424
Kamran.Ahmed@moffitt.org
Sasha Beyer, MD, PhD
Ohio State University Comprehensive Cancer Center
Interventions
  • Radiation: Stereotactic Radiosurgery (SRS) — Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
  • Drug: Abemaciclib — Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
  • Drug: Endocrine therapy — Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
Study Locations (2 sites)
Moffitt Cancer Center, Tampa, Florida 33612 United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * HR+ breast cancer to fulfill the requirement of HR+ disease, a breast cancer must express (≥ 1%), by immunohistochemistry (IHC), at least 1 of the hormone receptors (estrogen receptor \[ER\] or progesterone receptor \[PR\]) as defined in the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines * To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization as defined by the ASCO / CAP Guidelines * ≤ 15 brain metastases eligible for stereotactic radiation * Able to swallow oral medications * Willing to comply with all study procedures and available for duration of the study * Measurable brain disease per RANO-BM criteria that can be measured in at least one dimension as ≥ 0.5 cm for both intact brain metastases and post-operative cavities * Eligible for SRS to brain metastases or to the post-operative bed following surgical resection * Maximum diameter of the largest intact brain metastases ≤ 4 cm * Eastern Cooperative Oncology Group performance status 0 to 2 * A formalin-fixed, paraffin-embedded tumor tissue block or 10 unstained slides of intracranial/extracranial tumor sample (archival or recent) for biomarker evaluation should be made available and submitted to the central lab for correlative studies. If attempts to obtain archival tissue are unsuccessful the patient may be enrolled. * Individuals with prior SRS/fractioned stereotactic radiotherapy (FSRT) treatment will be allowed if active measurable disease has not previously been treated with radiation therapy * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 7 days of the first dose of abemaciclib * WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s), and for three weeks following the last dose of abemaciclib * Adequate organ function as defined in protocol Exclusion Criteria: * Presence of leptomeningeal disease * Prior receipt of whole brain radiation therapy * Prior receipt of abemaciclib in the setting of brain metastases or in the past 6 months for the treatment of metastatic disease. * All toxicities attributed to prior anticancer therapy must have been resolved to Grade 1 (NCI CTCAE Version 5) or baseline before administration of study drug(s) other than: a. Toxicities attributed to prior anticancer therapy that either are not expected to resolve and/or result in long-lasting sequelae, such as neuropathy after platinum-based therapy b. Toxicities that are not expected to interfere with study treatment, such as fatigue, alopecia, or grade 2 hematologic toxicity * Women who are pregnant or breastfeeding * The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea) * The patient has active systemic bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\]. Screening is not required for enrollment * The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest * History of prior malignancy within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS of \>90%), such as but not limited to, non-melanoma skin carcinoma, or stage I endometriod uterine cancer, and others at the discretion of the PI. * Major surgery or significant traumatic injury that has not been recovered from by 14 days before the initiation of study drug * Current or prior participation in a study of an investigational agent or investigational device within 2 weeks of first dose of study treatment * History of allergy or hypersensitivity to any of the study drugs or study drug components * Prisoners or individuals who are involuntarily incarcerated
Conditions Triple Negative Breast Cancer
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Predictive biomarkers of response to combination chemotherapy and immune-checkpoint inhibitors are urgently needed to help tailor treatment recommendations for patients with early-stage TNBC. Tumour-associated microbiota in primary breast tumours represent promising and novel candidate biomarkers modulators of the efficacy of therapies for patients with TNBC. It has been shown that microbes colonizing breast tumours can modulate the efficacy of commonly used drugs and that the microbiome of breast tissue biopsies could represent a new biomarker. Data on the microbiome of patients with cancer indicate the potential for a new class of bacteria-based oncological biomarkers, for exploitation in precision oncology.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • To evaluate the breast cancer microbiome pre- and post-therapy, in patients with early stage TNBC undergoing neoadjuvant systemic therapy (Through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-02
Completion: 2027-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University College Cork
Collaborators: Breast Cancer Research Foundation
Contact Information
Study Contact:
Roisin Connolly
021 4922687
roisin.connolly@ucc.ie
Roisin Connolly
0214922687
Cork University Hospital
Interventions
N/A
Study Locations (1 sites)
Cork University Hospital, Cork, Munster Ireland
Eligibility Criteria
Inclusion Criteria: 1. Be willing and able to provide written informed consent for the trial in accordance with national/local guidelines. 2. Be a male or female subject 18 years of age on day of signing informed consent. 3. Histologically proven infiltrating carcinoma of the breast on core needle biopsy that is: HER2 negative in primary tumour pre-treatment by local pathology assessed according current ASCO/CAP guidelines: In situ hybridization non-amplified (ratio of HER2 to CEP17 \< 2.0 or single probe average HER2 gene copy number \< 4 signals/cell), OR Immunohistochemistry (IHC) 0 or IHC 1+. ER and PR negative in primary tumour pre-treatment defined as \< 10% of cells expressing hormonal receptors via IHC analysis by local laboratory assessment. 4. Unresected, untreated breast cancer planned to undergo neoadjuvant systemic therapy, that meets one of the following clinical stages (see Appendix A): o T2, T3, or T4a-d lesion, any N, M0 5. Be willing to undergo mandatory research biopsy procedure at baseline (up to 4 core samples may be taken from this procedure). Exclusion Criteria: 1. Patients who are pregnant or breast-feeding 2. Current use of any investigational agents 3. History or current evidence of any condition, therapy, lab abnormality or other circumstance that in the opinion of the investigator might expose the subject to risk by participating in the trial, confound the results of the trial, or interfere with the subject's participation for the full duration of the trial.
Conditions Melanoma (Skin Cancer), Breast Cancer, B...
Phase PHASE1
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

To find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Alpelisib + Pembrolizumab — Given by mouth (PO) Given by vein (IV)

Primary Outcomes

  • Adverse Events (Through study completion; an average of 1 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-10-15
Completion: 2029-08-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Ecaterina Dumbrava, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Ecaterina Dumbrava, MD
(713) 792-3934
eeileana@mdanderson.org
Ecaterina Dumbrava, MD
713-792-3934
eeileana@mdanderson.org
MD Anderson Cancer Center
Interventions
  • Drug: Alpelisib + Pembrolizumab — Given by mouth (PO) Given by vein (IV)
Study Locations (1 sites)
MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Patients must be 18 years or older. 2. Patients must be willing and able to provide informed consent. 3. In the dose escalation, patients must have histologically documented locally advanced, unresectable, or metastatic melanoma or TNBC that has progressed on treatments that are known to prolong survival or for which no standard treatment is available or refused such therapy. Presence of active brain metastases is not required. Patients with active metastases as defined below can be eligible in the dose escalation. 4. In the dose expansion, patients must have histologically documented locally advanced, unresectable, or metastatic melanoma or TNBC that has progressed on treatments that are known to prolong survival or for which no standard treatment is available or refused such therapy. 1. Melanoma patients without brain metastases who have progressed on an anti-PD-1 or anti-PD-L1-based regimen. 2. Melanoma patients with active and untreated brain metastases who have progressed on an anti-PD-1 or anti-PD-L1-based regimen. 3. TNBC patients (defined as ER \<1%, HER2 0, 1+, 2+, and fluorescence in situ hybridization negative) with active untreated brain metastases. Prior treatment with anti-PD-1/anti-PD-L1 is not required. 5. All patients must have had a brain magnetic resonance imaging (MRI) scan in the previous 28 days to confirm eligibility for the following cohorts: 1. Dose escalation and dose expansion Cohort 1: Confirmed absence of untreated brain metastases in patients with histologically confirmed advanced melanoma. Prior surgery for brain metastases must have been completed at least 4 weeks prior study treatment initiation, whole brain radiation therapy must have been completed at least 3 weeks prior to study treatment initiation, and stereotactic radiosurgery must have been completed within 7 days prior to study treatment initiation. 2. Dose escalation and dose expansion Cohorts 2 and 3: At least one confirmed measurable untreated brain lesion ≥ 0.5 cm and \< 3.0 cm in the longest axis. 6. Has measurable disease based on the RECIST v1.1. 7. Has adequate organ function as defined in Table 2: 8. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 4). 9. Has a life expectancy of at least 12 weeks. 10. Able to swallow and retain orally administered medication. 11. In the dose expansion, patients with EC disease must be willing to provide tissue from a newly obtained, safely accessible core or excisional biopsy lesion at pre-treatment and at least one time point while on study treatment. Correlative biopsies will be optional in the dose escalation portion of the study. Newly obtained biopsy is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of study treatment on Day 1 without intervening systemic therapy. 12. Women of childbearing potential (WOCBP) should have a negative urine pregnancy test within 72 hours prior to receiving the first dose of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 13. Alpelisib and pembrolizumab can cause fetal harm when administered to a pregnant woman. Therefore, WOCBP must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of screening through 4 months after the last dose of study treatment. Refer to Pregnancy Assessment Policy MD Anderson Cancer Center (MDACC) Institutional Policy # CLN1114. This includes all female patients between the onset of menses and 55 years unless the patient presents with an applicable exclusionary factor such as one of the following: 1. Postmenopausal (no menses in ≥ 12 consecutive months) 2. History of hysterectomy or bilateral salpingo-oophorectomy 3. Ovarian failure (follicle-stimulating hormone and estradiol in menopausal range and have received whole pelvic radiation therapy) 4. History of bilateral tubal ligation or another surgical sterilization procedure 14. Approved methods of birth control are as follows: hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device, tubal ligation or hysterectomy, patient/partner post vasectomy, implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the study and the study treatment washout period is an acceptable practice; however, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 15. Male patients with partner(s) of childbearing potential must agree to use adequate contraception from the time of screening through 4 months after the last dose of study treatment. Exclusion Criteria: 1. Has a history of or active autoimmune disease, as follows: history of inflammatory bowel disease, history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], systemic lupus erythematosus, autoimmune vasculitis \[e.g., Wegener's granulomatosis\]), motor neuropathy considered of autoimmune origin (e.g., Guillain-Barré syndrome and myasthenia gravis), or history of autoimmune thyroiditis (patients may be eligible if their current thyroid disorder is treated and stable with replacement or other medical therapy). 2. Has active infection or had a serious general medical condition(s) (such as vascular accident) in the past 6 months. 3. Any unresolved \> Grade 1 toxicity (per CTCAE v5.0) from previous anticancer therapy or previously administered agent at the time of enrollment, except for alopecia and Grade 2 anemia (if hemoglobin is \> 9 g/dL). Note: If the patient received major surgery, he/she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. 4. Patients who received chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting study treatment. 5. Presence of any clinically significant gastrointestinal abnormality or other condition(s) (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) that may alter absorption such as malabsorption syndrome or major resection of the stomach or substantial portion of the small intestine based on investigator discretion. 6. Previous major surgery within 14 days prior to enrollment. 7. Evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, hepatic, renal, or cardiac disease). 8. Established diagnosis of diabetes mellitus type I or uncontrolled type II (based on fasting blood glucose and HbA1c \[see inclusion criteria #4\]). 9. History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis. 10. History of severe cutaneous reaction, such as SJS, erythema multiforme (EM), TEN, or drug reaction with eosinophilia and systemic symptoms (DRESS). 11. Based on average of triplicate 12-lead electrocardiogram (ECG), a mean resting QTc interval using Fridericia formula \> 450 msec for males and \> 470 msec for females at screening or a history of congenital long QT syndrome or QTc \> 480 msec for patients with a bundle branch block. 12. History or evidence of cardiovascular risk including any of the following: 1. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting, or bypass grafting within 6 months prior to enrollment. 2. Class III or IV heart failure as defined by the New York Heart Association functional classification system. 3. Known left ventricular ejection fraction \< 50%. 4. Known cardiac metastases. 13. Poorly controlled hypertensio
Conditions Diabetes Type 2, Coronary Artery Disease
Phase PHASE2, PHASE3
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Canagliflozin — Canagliflozin tablet 300mg PO daily
  • Drug: Placebo — Placebo tablet

Primary Outcomes

  • TBR (Tissue-to-blood ratio) of the most-diseased segment (MDS) of the ascending aorta (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2024-11-15
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ottawa Heart Institute Research Corporation
Principal Investigators:
  • Kevin Boczar, MD (PRINCIPAL_INVESTIGATOR) - Ottawa Heart Institute Research Corporation
Contact Information
Study Contact:
Kevin Boczar, MD
613 696 7000
kboczar@ottawaheart.ca
Chantal L
6136967000
clefebvre@ottawaheart.ca
University of Ottawa Heart Institute
Interventions
  • Drug: Canagliflozin — Canagliflozin tablet 300mg PO daily
  • Drug: Placebo — Placebo tablet
Study Locations (1 sites)
University of Ottawa Heart Institute, Ottawa, Ontario K1Y 4W7 Canada
Eligibility Criteria
Inclusion Criteria: * 1\) Stable CAD (over 60 days post-myocardial infarction). * 2\) Diabetes * 3\) given informed consent. Exclusion Criteria: 1. severe LV dysfunction (EF\<50%); 2. decompensated heart failure; 3. active infection (e.g. pneumonia, active skin infections, and on antibiotics); 4. active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate)); 5. pregnancy (all women of child bearing potential will have a negative BHCG test; 6. breastfeeding; 7. Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception. 8. glomerular filtration rate (GFR) \<50 ml/min/1.72m2; 9. Use of p-glycoprotein inhibitor (e.g. cyclosporine, verapamil, or quinidine) or a strong CYP3A4 inhibitor (e.g. ritonavir, clarithromycin, or ketoconazole); 10. Hemoglobin \< 105(women) \<110 (men) g/L; WBC \< 3.0x 10(9)/L, platelet count\< 110x 10(9)/L; 11. Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease or with alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal. 12. unable to give informed consent;
Conditions Stroke Recurrence, Type 2 Diabetes, Pred...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Objectives: This study aims to test whether a mobile app called PortionSize Ed can help adults who have had a recent stroke and also have prediabetes or type 2 diabetes improve their diet. Specifically, we want to see if the app can help people follow a Mediterranean-style diet, which may lower the risk of future strokes and improve overall health. The main goals are to: * Test if the app is easy to use and acceptable to participants. * See whether the app helps people follow a healthier diet. * Look at changes in health indicators like blood sugar, cholesterol, blood pressure, and body fat. Design and Outcome: This is a randomized controlled pilot study that will involve 40 participants. All participants will be recruited from Queen's Medical Center after a recent stroke and will be randomly assigned to one of two groups: Intervention Group: Uses the full PortionSize Ed app, gets weekly reminders and educational videos, and has 3 sessions with a registered dietitian (RDN) over 12 weeks. Control Group: Uses a basic version of the app without feedback or RDN support, and receives usual care for stroke recovery. All participants will continue to receive standard care from Queen's, including the My Stroke Recovery Guide. The study lasts 12 weeks, with visits at the beginning and end to collect health data and feedback on the app. Schedule and Type of Evaluations/Interventions: Participants will complete the following: Baseline and Week 12 Visits: In-person assessments for blood sugar (HbA1c), cholesterol, blood pressure, height, weight, and body composition (using DXA, BIA, and 3D imaging), as well as surveys about their diet and activity levels. Intervention Group Only: * Three virtual counseling sessions with a registered dietitian (Week 1, 6, 12) * Weekly nutrition goal tracking and texting with the dietitian * Watching short educational videos through the app * Receiving app-based feedback on how well their diet follows Mediterranean Diet recommendations Duration of Study: The study will last 12 weeks for each participant, with an optional long-term follow-up using medical records. Sample Size and Population: The study will include 40 adults, ages 30 to 65, who: * Recently experienced a stroke * Have a history of prediabetes or type 2 diabetes * Are medically stable and able to use a smartphone (or willing to use a study-provided iPhone) * People will be excluded if they have severe swallowing issues, cognitive problems, or dietary needs that would make it hard to follow a Mediterranean-style diet.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: PortionSize Ed + MedDiet Support — Full PortionSize Ed app access with personalized dietary feedback, educational videos, 3 virtual sessions with a registered dietitian (RDN), standard of care (for post-stroke with pre-diabetes or T2D) over 12 weeks.
  • Behavioral: Standard of care for Stroke and Prediabetes or T2D — Uses a basic version of the PortionSize Ed app without feedback or RDN support and receives usual care for stroke recovery and prediabetes or T2D for 12 weeks.

Primary Outcomes

  • Participant Acceptability of PortionSize Ed App (11 months)
  • Participant Retention Rate (11 months)
  • Participant Satisfaction with Study Procedures and App Features (11 months)
  • Participant Engagement with the PortionSize Ed App (11 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-01
Completion: 2026-12-31
Eligibility
Age: 30 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Hawaii
Collaborators: Queen's Medical Center
Contact Information
Study Contact:
Chloe P Lozano, PhD, MS, GradDip Dietetics
(808) 586-3010
cpanizza@hawaii.edu
Chloe P Lozano, PhD, MS, GradDip Dietetics
8086400339
cpanizza@hawaii.edu
University of Hawaii Cancer Center
Interventions
  • Behavioral: PortionSize Ed + MedDiet Support — Full PortionSize Ed app access with personalized dietary feedback, educational videos, 3 virtual sessions with a registered dietitian (RDN), standard of care (for post-stroke with pre-diabetes or T2D) over 12 weeks.
  • Behavioral: Standard of care for Stroke and Prediabetes or T2D — Uses a basic version of the PortionSize Ed app without feedback or RDN support and receives usual care for stroke recovery and prediabetes or T2D for 12 weeks.
Study Locations (1 sites)
University of Hawaii Cancer Center, Honolulu, Hawaii 96813 United States
Eligibility Criteria
Inclusion Criteria: * Aged 30 to 65 years * Recent stroke (ischemic, hemorrhagic or Transient Ischemic Attack), within 1-14 days prior to enrollment * Confirmed diagnosis of prediabetes or type 2 diabetes, based on HbA1c results * Medically stable and cleared for oral diet and physical activity by the attending physician * Cleared for thin liquids and regular textures by physician * Capable of providing informed consent * Able to speak and read English * Owns a smartphone OR is willing to use a study-provided iPhone * Has sufficient cognitive and physical function to use a mobile app * Willing to participate in all study procedures and available for the 12-week duration Exclusion Criteria: * Severe dysphagia that prevents oral intake * Type 1 diabetes * Cognitive impairment (e.g., dementia, post-stroke confusion) that precludes consent or compliance, as judged by the clinical care team * Current participation in another interventional clinical trial * Pregnant or breastfeeding, or planning to become pregnant during the study period * Unwilling or unable to provide written informed consent * Serious comorbid conditions that, in the opinion of the
Conditions Type 2 Diabetes
Phase NA
Enrollment 200
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Being active is one way to reach better blood sugar control and heart health in type 2 diabetes. The investigators developed a strategy to help people with type 2 diabetes walk more. They track their steps with a step counter and set targets with their doctor through a kind of 'step prescription.' While this strategy helps people increase their physical activity, it can be useful to have support besides the clinic visits. Their partner might be a good person to help. Partners often have similar activity levels. Partners of people with type 2 diabetes are also more likely to develop type 2 diabetes. There are good reasons to work together! However, not all partners communicate in a way that helps them work together effectively. The investigators are going to give a step counter and step prescriptions to a large group of people with type 2 diabetes. The partners will also receive counters and step prescriptions. Half of the couples will be randomized (assigned to a group based on something equivalent to a coin toss) to participate in online or in-person sessions with a counselor. They will work together to figure out how to communicate more kindly and effectively. The investigators will see if the people with these sessions wind up having higher steps and better sugar control than the people who do not. To figure out in which types of couples the strategy works, The investigators will also divide the couples into groups based on the type of marriage that they have (figured out through a questionnaire) and body size. The investigators will see if the counseling strategy helps in both 'high' and 'low' quality relationships and if couples where both partners have extra weight respond differently to the strategy than other couples. During the trial, if The investigators see that the strategy is not working well in one particular group of people, The investigators may recruit fewer in this group and more in the others. The investigators will do this in consultation with specialized statisticians who will look at the data at specific points in time. This is a way of making sure that the investigators are testing the right strategy in the right group, increasing the 'efficiency' and relevance of the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Step Count tracking and goals — We will provide participants and partners with Fitbits for the duration of the trial. After one week of step counting, the next week target will be to increase by 500 steps/day if baseline \< 5000 steps/day; increase by 750 steps/day if baseline 5000 to 7,500 steps/day; and increase by 1,000 steps/day if baseline \> 7,500 steps/day). Each week thereafter, study staff will pull the step data and apply an algorithm to generate new targets for the next week. In our algorithm, subsequent targets are higher if the participant exceeds prior week targets, and lower/unchanged if below target. This is similar to the algorithm we used in our trial ACTIVE PATIENT GDM (Dasgupta K, Chan D, Bond R, Garfield N, Coolen J, Halperin IJ, Peters TM, et al. Step and weight tracking with targets and coaching interventions in gestational diabetes: A randomized factorial feasibility trial. Diabetes Res Clin Pract. 2025 Jun;224:112241. doi: 10.1016/j.diabres.2025.112241. Epub 2025 May 9. PMID: 40349846.)
  • Behavioral: Dyadic coping intervention — Couples will participate in 8 one-hour coaching sessions over 12 weeks (virtual, in-person, or a combination, as preferred). The sessions aim to enhance the couple's understanding of how they influence each other. Both couple members will explore their preferences in terms of ways of communicating and supporting one another's goals. We will use changes in steps as a context to explore how partners can effectively support and "coach" each other without without eliciting behavioural reactance. We will use are goal setting, action planning, self-monitoring, graded tasks, social environment restructuring, and social support. The coaches will be psychology students. They will receive structured training on the coaching strategy from a licensed mental health professional. We will record the sessions for fidelity and quality assurance purposes. All coaches will meet weekly with the supervising licensed mental health professional.

Primary Outcomes

  • Change in steps/day (The primary outcome is at 24 weeks and a secondary outcome will be at 12 weeks (midpoint))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2027-12
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators: Diabetes Canada
Principal Investigators:
  • Kaberi Dasgupta, MDCM, MSc, FRCPC (PRINCIPAL_INVESTIGATOR) - Research Institute of the McGill University Health Centre
  • Jean-Philippe Gouin, PhD (PRINCIPAL_INVESTIGATOR) - Concordia University, Montreal
  • Shirin Golchi, PhD (PRINCIPAL_INVESTIGATOR) - McGill University
Contact Information
Study Contact:
Debora Rosa, BSc
1-438-346-0479
debora.rosa@rimuhc.ca
Deborah Chan, BSc
1-514-934-1934
debbie.chan@rimuhc.ca
Debora Rosa, BSc
1-438-346-0479
debora.rosa@rimuhc.ca
St. Mary's Hospital
Interventions
  • Behavioral: Step Count tracking and goals — We will provide participants and partners with Fitbits for the duration of the trial. After one week of step counting, the next week target will be to increase by 500 steps/day if baseline \< 5000 steps/day; increase by 750 steps/day if baseline 5000 to 7,500 steps/day; and increase by 1,000 steps/day if baseline \> 7,500 steps/day). Each week thereafter, study staff will pull the step data and apply an algorithm to generate new targets for the next week. In our algorithm, subsequent targets are higher if the participant exceeds prior week targets, and lower/unchanged if below target. This is similar to the algorithm we used in our trial ACTIVE PATIENT GDM (Dasgupta K, Chan D, Bond R, Garfield N, Coolen J, Halperin IJ, Peters TM, et al. Step and weight tracking with targets and coaching interventions in gestational diabetes: A randomized factorial feasibility trial. Diabetes Res Clin Pract. 2025 Jun;224:112241. doi: 10.1016/j.diabres.2025.112241. Epub 2025 May 9. PMID: 40349846.)
  • Behavioral: Dyadic coping intervention — Couples will participate in 8 one-hour coaching sessions over 12 weeks (virtual, in-person, or a combination, as preferred). The sessions aim to enhance the couple's understanding of how they influence each other. Both couple members will explore their preferences in terms of ways of communicating and supporting one another's goals. We will use changes in steps as a context to explore how partners can effectively support and "coach" each other without without eliciting behavioural reactance. We will use are goal setting, action planning, self-monitoring, graded tasks, social environment restructuring, and social support. The coaches will be psychology students. They will receive structured training on the coaching strategy from a licensed mental health professional. We will record the sessions for fidelity and quality assurance purposes. All coaches will meet weekly with the supervising licensed mental health professional.
Study Locations (3 sites)
St. Mary's Hospital, Montreal, Quebec H3T 0A2 Canada
Jewish General Hospital, Montreal, Quebec H3T 1E2 Canada
McGill University Health Centre, Montreal, Quebec H4A 0B1 Canada
Eligibility Criteria
Inclusion Criteria: * (i) Index participant has T2D; * (ii) Index participant 45 years of age or older; * (iii) Index participant and partner: Co-habiting with a partner (same or different sex) for two or more years; * (iv) Index participant and partner: Absence of gait difficulties or other co-morbid conditions that impede walking in the index participant; * (v) Willingness to complete an audiovisual recording of a conversation between the couple members to capture couple communication styles * (vi) Index participant and partner Smartphone and Internet access.